Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Seattle tests Short-Stay center to curb opioid overdose deaths

NCT ID NCT06768814

Knowledge-focused Sponsor: University of Washington Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing a new center in Seattle where people who have had an opioid overdose can stay for up to 24 hours. The center offers monitoring, medication for opioid use disorder, and connections to ongoing care. Researchers will compare outcomes like repeat overdoses and treatment initiation among those who use the center versus those who don't. The goal is to see if this approach helps prevent future overdoses and improves access to recovery services.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could show that a short-stay stabilization center after an opioid overdose reduces repeat overdoses and improves access to treatment.
What could go wrong
This is an early-stage observational study, not a controlled trial, so results may not prove cause and effect. The center is only in Seattle, so findings may not apply elsewhere.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 40,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2024

Expected to finish

May 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Verbally consents to transfer of care to SASC. 2. Awake and oriented to person and place, with no significant deficits in mental status or neurological function. 3. Age \>=18 4. Patent airway and effective respirations with adequate oxygenation. 5. Stable heart rate and blood pressure, with no evidence of cardiac arrhythmias or other significant cardiovascular disfunction. 6. Vitals: * Heart rate: 45-130 * Blood pressure: systolic 95-190, diastolic 50-120 * Respiratory rate: 10-24 * SpO2: \>92 on room air or supplemental O2 via nasal cannula. * SpO2 \<92% with supplemental O2 requires ED transfer. * EtCO2: \<50 * Temperature: 95.5-100.3 F * Blood glucose (if indicated): 60-300 7. No signs of head trauma: * Dizziness or loss of balance * Blurred vision or double vision * Sensitivity to light or noise * Seizures or convulsions * Weakness or numbness in the arms or legs * Persistent or worsening headache * CSF or blood leaking from the nose or ears * Unequal pupils or pupils that are slow to react to light. 8. No signs of other traumatic injury or medical needs requiring immediate treatment. 9. No signs of respiratory infection. Screen for COVID-19. See COVID-19 Screening protocol. Exclusion Criteria: \- People under 18 and who do not meet SASC admission criteria will be excluded.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Opioid use are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Harm Reduction opiate dependence Opiate Overdose opioid abuse

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Opioid use Opioid use disorder

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Downtown Emergency Service Center's Overdose Recovery and Care Access Centers

    RECRUITING

    Seattle, Washington, 98104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.